eMJA: In other journals - 18 February 2002

Med J Aust 2002; 176 (4): . || doi: 10.5694/j.1326-5377.2002.tb04353.x
Published online: 18 February 2002

It remains unclear whether second-generation oral contraceptives, containing levonorgestrel, or third-generation formulations, containing desogestrel or gestodene, have a more favourable risk profile with regard to myocardial infarction. Third-generation preparations are associated with at least a doubling of the risk of venous thrombosis; however, it has been suggested that they may protect against myocardial infarction by having a more favourable effect on lipid profile. A recent Dutch nationwide, population-based, case–control study enrolled 248 women aged 18–49 years who had a first myocardial infarction (MI) between 1990 and 1995, and 925 matched controls. Use of the OCP was associated with a doubling in MI rates, but the results suggested that second-generation formulations produced a higher risk than the third-generation preparations (OR, 2.5 [95% CI, 1.5–4.1] v 1.3 [95% CI, 0.7– 2.0]). However, the authors note that a previous study suggested the reverse, and that neither study was conclusive due to wide confidence intervals. Among women who had used the OCP, the risk of MI was highest among those who smoked (OR, 13.6), had diabetes (OR, 17.4) or hypercholesterolaemia (OR, 24.7).



remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.